Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.

PMID:
19436050
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.

Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, Hernández JM, Sanchez-Guijo FM, del Cañizo MC, Gutiérrez NC, San Miguel JF.

Leukemia. 2009 Aug;23(8):1515-27. doi: 10.1038/leu.2009.65. Epub 2009 Apr 9.

PMID:
19357701
[PubMed - indexed for MEDLINE]
3.

Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K.

Oncogene. 2009 Jan 15;28(2):231-42. doi: 10.1038/onc.2008.385. Epub 2008 Oct 13.

PMID:
18850009
[PubMed - indexed for MEDLINE]
4.

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S.

Mol Cancer Res. 2008 Aug;6(8):1356-64. doi: 10.1158/1541-7786.MCR-08-0108.

PMID:
18708367
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Zdzisińska B, Bojarska-Junak A, Dmoszyńska A, Kandefer-Szerszeń M.

Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):207-21. doi: 10.1007/s00005-008-0022-5. Epub 2008 May 30.

PMID:
18512025
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S.

Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40.

PMID:
18489772
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Cancer biology. All in the stroma: cancer's Cosa Nostra.

Marx J.

Science. 2008 Apr 4;320(5872):38-41. doi: 10.1126/science.320.5872.38. No abstract available.

PMID:
18388269
[PubMed - indexed for MEDLINE]
8.

Multiple myeloma.

Kyle RA, Rajkumar SV.

Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022. Review.

PMID:
18332230
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells.

Trivedi P, Hematti P.

Exp Hematol. 2008 Mar;36(3):350-9. doi: 10.1016/j.exphem.2007.10.007. Epub 2008 Jan 7.

PMID:
18179856
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma.

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):182-93. Epub 2007 Sep 12.

PMID:
17855157
[PubMed - indexed for MEDLINE]
11.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL.

Cancer Cell. 2007 Aug;12(2):131-44.

PMID:
17692805
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.

Cancer Cell. 2007 Aug;12(2):115-30.

PMID:
17692804
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.

Nat Rev Cancer. 2007 Aug;7(8):585-98. Review.

PMID:
17646864
[PubMed - indexed for MEDLINE]
14.

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

Anderson KC.

Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62. Review.

PMID:
17379101
[PubMed - indexed for MEDLINE]
15.

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T, Bourin P.

Leukemia. 2007 May;21(5):1079-88. Epub 2007 Mar 8.

PMID:
17344918
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R.

Leukemia. 2007 Mar;21(3):529-34. Epub 2007 Jan 18.

PMID:
17230230
[PubMed - indexed for MEDLINE]
17.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.

Blood. 2007 Apr 15;109(8):3177-88. Epub 2006 Dec 21.

PMID:
17185464
[PubMed - indexed for MEDLINE]
Free Article
18.

Integrating cell-signalling pathways with NF-kappaB and IKK function.

Perkins ND.

Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62. Review.

PMID:
17183360
[PubMed - indexed for MEDLINE]
19.

Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.

Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J.

Leukemia. 2007 Jan;21(1):158-63. Epub 2006 Nov 9.

PMID:
17096013
[PubMed - indexed for MEDLINE]
20.

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E.

Cytotherapy. 2006;8(4):315-7.

PMID:
16923606
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk